Method of determining a site of inflammation utilizing elam-1 ligands

Patent 5143712 Issued on September 1, 1992. Estimated Expiration Date:

January 7, 2011. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Inventors

Assignee

Glycomed Incorporated

Application

No. 637868 filed on 01/07/1991

US Classes:

424/1.73, Attached to carbohydrate compound; derivative thereof (e.g., DNA, nucleotide, nucleoside, sugar, starch, tannin, saccharide, polysaccharide, cellulose, O-, N- and S-glycoside, vitamin B12)424/1.13, In aerosol, fine spray, effervescent, pressurized fluid, vapor or gas, or complete composition therefor424/1.17, Attached to or within viable or inviable whole micro-organism, cell, virus, fungus or specified sub-cellular structure thereof (e.g., platelet, red blood cell)424/1.25Dissolving or eluting from solid or gel matrix (e.g., capsule, tablet)

Examiners

Primary: Maples, John S.

Attorney, Agent or Firm

Bozicevic; Karl, Giotta; Gregory J.

Foreign Patent References

9013300 WO. 11/13/1990

International Classes

A61K 049/02
A61K 049/00

Abstract

Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation. The ligands are encompassed by general structural formula I as follows: ##STR1## wherein one of A and B is hydrogen and one is an N-acetyl neuraminic acid residue; D and E are each independently hydrogen or a fucose residue; n is an integer of from 0 to 10 with the proviso that if n is 0, E is a fucose residue; F is hydrogen, a lactosylceramide residue or a linking group; and molecules equivalent to a compound of formula I regarding its ability to bind to an ELAM-1 receptor to the same degree as a compound of formula I.